10x Genomics (TXG) Tops Q2 EPS by 10c, Beats on Revenue

10x Genomics (NASDAQ: TXG) reported Q2 EPS of ($0.14), $0.10 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $151.04 million versus the consensus estimate of $146.64 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• JPMorgan Downgrades HomeCo Daily Needs REIT (HDN:AU) to Neutral
• Macquarie Upgrades DiDi Global (DIDIY) to Outperform